Proteina Co., Ltd.

Proteina Co., Ltd. is a biotechnology company focused on advancing healthcare through sophisticated protein-protein interaction (PPI) analysis. Founded in 2015 and headquartered in Seoul, South Korea, the company specializes in the development of innovative single-molecule co-immunoprecipitation (SMCIP) technology, enabling the quantitative measurement and profiling of PPIs at a highly granular level. This proprietary platform supports the identification of novel disease biomarkers and therapeutic targets, accelerating both disease diagnostics and drug discovery processes. By providing precise and reproducible PPI data, Proteina Co., Ltd.'s technology allows for integration of complex datasets from different sites and times, facilitating translational research and clinical application. The company plays a vital role in the pharmaceuticals and biotech sector, particularly in areas such as oncology, where real-time analysis of signaling pathways can inform targeted therapy decisions and guide drug resistance profiling. Proteina Co., Ltd.'s contributions underpin critical advancements in personalized medicine and biomarker-driven research within the broader biotechnology and medical research landscape.